Loading company
Nyxoah SA
NYXH · Nasdaq · Healthcare · Medical Devices
$1.39-14.5%Sep 29 close
- 1M
- -7.0%
- 6M
- -56.3%
- 1Y
- -72.0%
- 5Y
- -95.1%
NYXH · Nasdaq · Healthcare · Medical Devices
$1.39-14.5%Sep 29 close
The quarter ending June 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2025 | 3 months toJun 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | $1.5M | $875.5K | +73.80% |
| Profit | -$419.00 | -$679.03 | +38.29% |
| Profit per share | -$0.63 | -$0.27 | -127.69% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Nyxoah SA has no earnings call transcript available.
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete 3 Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and receipt of approval from the FDA in August 2025.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Nyxoah SA filed on August 5, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.